VRTX

Vertex Pharmaceuticals Inc

VRTX, USA

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

https://www.vrtx.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VRTX
stock
VRTX

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wealth Enhancement Advisory Services LLC MarketBeat

Read more →
VRTX
stock
VRTX

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bailard Inc. MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$493.72

Analyst Picks

Strong Buy

14

Buy

4

Hold

14

Sell

1

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

34.02

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

7.20

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

6.25 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.36 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

37.04 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.44

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 102.17% of the total shares of Vertex Pharmaceuticals Inc

1.

Capital World Investors

(11.2064%)

since

2025/06/30

2.

Vanguard Group Inc

(9.3505%)

since

2025/06/30

3.

BlackRock Inc

(8.5307%)

since

2025/06/30

4.

Capital Research Global Investors

(6.2827%)

since

2025/06/30

5.

Capital Group Growth Fnd of Amer Comp

(4.7307%)

since

2025/06/30

6.

American Funds Growth Fund of Amer A

(4.7307%)

since

2025/06/30

7.

State Street Corp

(4.5927%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.1487%)

since

2025/07/31

9.

FMR Inc

(2.4987%)

since

2025/06/30

10.

Vanguard 500 Index Investor

(2.4793%)

since

2025/07/31

11.

Jennison Associates LLC

(2.3993%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.3124%)

since

2025/06/30

13.

JPMorgan Chase & Co

(2.2892%)

since

2025/06/30

14.

Invesco QQQ Trust

(2.0644%)

since

2025/08/29

15.

American Funds American Balanced A

(1.9212%)

since

2025/06/30

16.

Wellington Management Company LLP

(1.8774%)

since

2025/06/30

17.

American Funds New Perspective A

(1.7798%)

since

2025/06/30

18.

Capital Group New Perspective Comp

(1.7798%)

since

2025/06/30

19.

AllianceBernstein L.P.

(1.7077%)

since

2025/06/30

20.

American Funds Invmt Co of Amer A

(1.6837%)

since

2025/06/30

21.

Capital Group Investment Co of Amer Comp

(1.6837%)

since

2025/06/30

22.

Loomis, Sayles & Company LP

(1.4873%)

since

2025/06/30

23.

NORGES BANK

(1.3964%)

since

2025/06/30

24.

American Funds AMCAP A

(1.3837%)

since

2025/06/30

25.

Capital Group AMCAP Composite

(1.3837%)

since

2025/06/30

26.

Morgan Stanley - Brokerage Accounts

(1.2994%)

since

2025/06/30

27.

Fidelity 500 Index

(1.2696%)

since

2025/07/31

28.

T. Rowe Price Associates, Inc.

(1.2324%)

since

2025/06/30

29.

American Funds Capital World Gr&Inc A

(1.218%)

since

2025/06/30

30.

Capital Group World Growth & Inc Cmp

(1.218%)

since

2025/06/30

31.

SPDR® S&P 500® ETF

(1.2101%)

since

2025/08/31

32.

iShares Core S&P 500 ETF

(1.2054%)

since

2025/08/31

33.

UBS Asset Mgmt Americas Inc

(1.1964%)

since

2025/06/30

34.

American Funds Washington Mutual A

(1.1636%)

since

2025/06/30

35.

Capital Group Wash Mutual Invtrs Comp

(1.1636%)

since

2025/06/30

36.

Vanguard Health Care Inv

(1.1088%)

since

2025/06/30

37.

Bank of America Corp

(1.0951%)

since

2025/06/30

38.

Northern Trust Corp

(1.0369%)

since

2025/06/30

39.

Capital Research & Mgmt Co - Division 3

(1.0281%)

since

2025/06/30

40.

HHG PLC

(1.0217%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

5.12

Latest Release

Date

2025-09-30

EPS Actual

4.8

EPS Estimate

4.61

EPS Difference

0.19

Surprise Percent

4.1215%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(8)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.